Pharmacology
DrugBankMechanism of Action
Nicotine is a stimulant drug that acts as an agonist at nicotinic acetylcholine receptors. These are ionotropic receptors composed up of five homomeric or heteromeric subunits. In the brain, nicotine binds to nicotinic acetylcholine receptors on dopaminergic neurons in the cortico-limbic pathways. This causes the channel to open and allow conductance of multiple cations including sodium, calcium, and potassium. This leads to depolarization, which activates voltage-gated calcium channels and allo
Metabolism
Primarily hepatic, cotinine is the primary metabolite.
Effect Profile
Curated + 41 ReportsStrong euphoria, focus, anxiety/jitters, and stimulation
Tolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Tolerance to stimulant and autonomic effects rises quickly with daily use and decays over weeks; values are approximate and inferred from dependence literature and user reports rather than controlled dosing studies.
Cross-Tolerances
Experience Report Analysis
ErowidDemographics
Gender Distribution
Age Distribution
Reports Over Time
Effect Analysis
ErowidEffects aggregated from 41 experience reports (41 Erowid)
Effect Sentiment Distribution
Confidence Distribution
Positive Effects 9
Adverse Effects 4
Form / Preparation
Most common forms and preparations reported
Redose Patterns
Redosing behavior across 25 reports
Harm Reduction
drugs.wikiReasoning for changes (key harm-reduction facts and sources): Nicotine dosing is highly route-dependent. Inhalation gives a near-immediate spike with short primary duration, while buccal products act slower/longer and patches provide stable, lower peaks—these differences influence overdose risk and redosing behavior. Erowid’s dosage page summarizes smoked, oral/buccal, intranasal ranges and typical patch delivery rates; the NCI PDQ shows marketed patch strengths and usage durations. These sources support the corrected/expanded ROA-specific dosing and time-course fields. Nicotine poisoning risk is significant with concentrated e-liquids and dermal/ocular exposure; national reviews document severe outcomes and rare fatalities, emphasizing glove use, child-resistant storage, and avoiding decanting into drink-like containers. Pure nicotine is not the primary driver of combustion-related disease; switching from smoking to nicotine-only products removes smoke toxicants and CYP1A2 induction, which can unexpectedly raise levels of caffeine, clozapine, olanzapine, and theophylline—so proactive dose/caffeine reductions and monitoring are important during transitions. Pregnancy/breastfeeding: guidance advises behavioral support first; if NRT is used, short-acting forms and daytime patch-only use (remove before bed) can reduce fetal exposure and vivid dreams; overall, NRT is considered far safer than continued smoking, but not risk-free. Timing buccal doses right after breastfeeding can reduce infant exposure. These points guide safer choices for pregnant or lactating people who cannot stop nicotine abruptly. Tobacco smoke (not pure nicotine) contains MAO-inhibiting beta-carbolines that enhance reinforcement; this clarifies that the MAOI warning relates mainly to smoke chemistry, while pharmaceutical MAOIs warrant caution because nicotine is a sympathomimetic. Pharmacokinetics: nicotine’s body half-life is about 2 hours (cotinine ~16–18 h, useful for testing), informing redose spacing and why cravings recur quickly with inhaled use. Practical HR tips embedded above: start low and titrate slowly; avoid stacking different nicotine products simultaneously without a plan; keep liquids locked away from children/pets; wear gloves/eye protection handling high-strength base; remove transdermal patches at night if disturbing dreams; avoid vaping battery misuse/poor-quality cells to reduce explosion/burn risk; and plan caffeine reduction when switching from smoking to nicotine-only delivery.
References
Drugs.wiki References
- Erowid Nicotine Dosage
- Erowid Nicotine Basics
- NCI PDQ: Cigarette Smoking—Health Risks and How to Quit (NRT tables)
- Treating Tobacco Use and Dependence: 2008 Update (drug interactions; smoke enzyme induction)
- NASEM: Public Health Consequences of E-Cigarettes (injuries and poisonings)
- NICE 2025 Tobacco Guideline (pregnancy NRT advice)
- LactMed: Nicotine (breastfeeding)
- IARC: Tobacco Smoke and Involuntary Smoking (nicotine half-life ~2 h)
- NCBI Bookshelf: Tobacco dependence—MAOIs in smoke